Craig S Miller
Dentist at Ashgrove Rd, Nicholasville, KY

6573041, Jun 3, 2003

Oct 29, 2001

09/984337

Craig S. Miller - Nicholasville KY
Robert J. Jacob - Lexington KY
Robert J. Danaher - Lexington KY

University of Kentucky Research Foundation - Lexington KY

C12Q 170

435 5, 435 6, 435353, 4352351

We previously described a novel in vitro model of a non-productive herpes simplex virus type 1 (HSV-1) infection in neurally-differentiated (ND)-PC12 cells that allows for inducible virus replication upon forskolin and heat stress (HS) treatment. In this research, we further characterized the model with respect to HSV-2 strain 333. We found that: (i) ND-PC12 cells are non-permissive to HSV-2 replication; (ii) HSV-2 can establish a quiescent infection, like HSV-1, in ND-PC12 cells with the transient use of acycloguanosine (ACV); however unlike HSV-1, anti-viral conditions are not obligatory to establish and maintain a quiescent state; (iii) the quiescent state is maintained in the presence of Vero cell cocultivation indicating that such cultures are free of infectious virus; and (iv) a high percentage of quiescently infected (QIF)-PC 12 cell cultures (80-100%) produce HSV-2 in response to forskolin and HS (43° C. , 3 h) treatment for as long as 4 weeks post infection. These findings indicate that ND-PC12 cells can harbor HSV-2 in a cryptic and non-productive state that is reversible.

6268124, Jul 31, 2001

Mar 19, 1999

9/272158

Craig S. Miller - Nicholasville KY
Robert J. Danaher - Lexington KY
Robert J. Jacob - Lexington KY

University of Kentucky Research Foundation - Lexington KY

C12Q 170, C12N 506

435 5

The present invention provides, inter alia, a PC12 cell quiescently infected with a neurotropic virus. Preferred quiescently-infected neural cells are those wherein the neurotropic virus is a neurotropic herpes virus. Methods related to these and other materials are also provided.

2012020, Aug 16, 2012

Aug 20, 2010

13/390619

John T. McDevitt - Houston TX, US
Craig S. Miller - Nicholasville KY, US
Jeffrey L. Ebersole - Lexington KY, US
Nicolaos Christodoulides - Austin TX, US
Pierre N. Floriano - Missouri City TX, US

C40B 30/04, G01N 33/573, G01N 33/566

506 9, 435 792, 435 74, 436501

Embodiments of the invention utilizes advanced detection methodologies, such as the lab-on-a-chip (LOC) technology, as a cost-effective, efficient, ultra-sensitive rapid method for diagnosing Acute Myocardial Infarction (AMI) in human subjects. In certain aspects, multiple biomarkers of AMI are concurrently detected and measured in serum and saliva to provide a more efficient, sensitive and accurate diagnosis of AMI.

2008030, Dec 4, 2008

Apr 16, 2008

12/104303

John T. McDevitt - Austin TX, US
Nicolaos Christodoulides - Austin TX, US
Pierre N. Floriano - Austin TX, US
Craig S. Miller - Lexington KY, US
Jeffrey L. Ebersole - Lexington KY, US

G01N 33/50

702 19

Embodiments of the invention include methods by which cardiac biomarkers are assigned an index (cardiovascular biomarker index-cardiobioindex, CBI) as a means to describe the utility of each biomarker, or combination of biomarkers for risk evaluation, diagnosis or prognosis of cardiovascular disease status.